$CANB “OTC Stock Review” Promoter Rank: 18/23 CAN B CORP. Newsletter 8:34:19 AM July 21, 2021

on July 21, 2021 Newsletters and Tags: , , , , , , , , , , with 0 comments

Overall Perfomance for "OTC Stock Review"

The following three charts can be used by potential investors to gauge the performance of "OTC Stock Review":

45%

9 out of 20 campaigns closed down on first day

30%

6 out of 20 campaigns closed up on first day

25%

5 out of 20 campaigns had no net effect

CANB Promotional Newsletter

The following is a newsletter released by "OTC Stock Review" promoting CAN B CORP.

Caution

The following newsletter has not been verified for accuracy or completeness.

Sh

office 404 856-9157

toll-free 866 692-6847

OTC Stock Review Award Winning Small Cap Stock Picks Since 2004

Cannabis stocks got hit hard because politicians can't get a bill through Congress to legalize weed. Like Congress ever does anything anyway Don't miss this play There's great news coming and not a lot of stock at this level.

Can B Corp OTC CANB - A Health and Wellness Company

Can B Corp. OTCQB CANB is a Health Wellness company providing the highest quality cannabidiol CBD products under the brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil and Duramed. CANB utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. CANB is also a license holder of the LifeGuard Brand in developing a line of consumer products. CANB has successfully launched Super Foods, a line of nutritional supplements. CANB owns and operates an RD and production facility in Lacey, WA and Green Grow Farms, a licensed hemp grower and cultivator in New York.

The Covid lockdown impacted sales in 2020. Look for an upswing in the next financial report.

For investors CANB has a very attractive share structure with about 16.6 million shares outstanding and a public float of only about 7.7 million shares. This small share structure can allow CANB stock to move up easily on positive developments. CANB also maintains the high standards for a fully reporting, OTCQB listing.

Key Events Subsequent to the End of 2020

Closed on the acquisition of assets and talent from a hemp derivative development and manufacturing group. A newly formed wholly owned subsidiary.

Botanical Biotech LLC BB, will be the new home for Florida-based research development laboratory and extraction facility for CANB. BB will focus on developing and implementing new pharmacokinetics technology and partnering with global and emerging brands to create innovative products and solutions that are positioned for sustainability and wellness and are culturally driven.

Signed a definitive agreement to acquire the assets of Imbibe Health Solutions LLC Imbibe, a developer and marketer of CBD and related products.

Imbibe has developed several CBD health and wellness products including topical salves, bath soaks, massage oils, and energy and dietary supplements. CANB will be putting Imbibe into one of its current inactive wholly-owned subsidiaries and will be renaming that subsidiary to reflect the products and culture that comes with the Imbibe acquisition.

Partnered with Dr. Karl Zarse who has launched ImmuneX2, a super immune boosting twice a day AMPM supplement. The two entities have developed a cooperative medical office affiliate program to share in the revenues of ImmuneX2. CANB will be targeting medical professionals and direct-to-consumer sales channels to proactively optimize immune systems.

Full Year 2020 Results Announced with Strong Gross Margin of 84%

Back in April CANB announced operating and financial results for the year ended December 31, 2020. During the year CANB took action to right-size expenses, focus its energy on higher margin revenue opportunities and improve positioning for future growth and profits.

Key Recent Highlights

Closed $2.8 million debt financing from an institutional investor, enabling the pay off and elimination of all prior outstanding convertible notes without penalty.

Tripled production with the installation of new high-speed equipment to expand production at its Pure Health Products facility in Lacey, Washington.

Raised a total of $4.0 million in equity with ongoing Reg A offering.

Cash balance of $1.7 million, as of April 2021.

Financial Highlights for the Year Ended December 31, 2020 vs. 2019

Gross Profit Increased from 74% in 2019 to 84% in 2020 a 10% Increase.

Operating Expenses Decreased $1.8 million a 24% Decrease.

Operating Loss Decreased $1.5 million a 26% Decrease.

Cash balance of $0.5 million.

Financial Results for the Year Ended December 31, 2020

Revenue for the year ended December 31, 2020 was $1,709,669, a decrease of $595,834 or 26%, compared to $2,305,503 for the year ended December 31, 2019. The decrease was due to the COVID-19 pandemic. Essentially, nationally elective surgeries were curtailed in favor of emergency use of all operating rooms and facilities, which dramatically curtailed the use of the CANB ultrasound device associated with patient recovery. Additionally, distributor and medical office sales of CANB main-line CBD products such as tinctures and salves were diminished due to closing and limited access to medical office facilities, again directly tied to the COVID pandemic.

For more information on Can B Corp. CANB visit and

Can B Corp

Price $0.51

NASDAQ Symbol CANB

Market Cap $8.5 million

Shares Outstanding 17.33 million

Sector Health Care

Industry Drugs, proprietaries, and sundries

52 Week HighLow $0.25$1.37

Address 960 South Broadway, Suite 120

Hicksville, NY 11801

Phone 516-595-9544

Website

Email

U.S. Reporting SEC Reporting

Audited Financials

Penny Stock Exempt

Independent Directors

All Canbiola Products are Tested by

Independent Laboratories and

Contain Zero THC

If you are having trouble geting a

good night's sleep, Can B can help.

Visit

Can B makes life better for both you

and your pets.

OTC Stock Review is not registered as an Investment Advisor or a BrokerDealer. The information in this newsletter is not an offer to buy or sell securities of the companies profiled. Information is for informative purposes, not intended as advice for investment and is subject to change without notice. OTC Stock Review is been compensated three thousand five hundred dollars a month and one hundred thousand five hundred shares of common stock restricted under Rule 144 to perform investor relations services for Can B. Officers and directors of OTC Stock Review may hold a long equity position in CANB and may from time to time trade in these securities for their own accounts. Information on each company is from public releases and can not be guaranteed by OTC Stock Review. Companies profiled herein may carry a high investment risk readers should carefully review profiled companies thoroughly with their investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled Companies and reflects the opinion of the author. Readers should obtain copies of the profiled Companys periodic reports filed with United States Securities and Exchange Commission, generally available at or . See our full disclaimer and Safe Harbour Statement at

If you no longer wish to receive these emails, please reply to this message with Unsubscribe in the subject line or simply click on the following link

to forward this email to a friend

OTC Stock Review
235 Peachtree St. NE
Suite 400
Atlanta, Georgia 30303
US

the marketing policy.

Last 2 Stock Promotions By "OTC Stock Review"

Symbol Company Start Date Close Change
ALAN Alanco Technologies, Inc. June 11, 2021 0.017 -13%
QSAM QSAM Biosciences Inc. April 21, 2021 0.380 4%